| ²é¿´: 320 | »Ø¸´: 2 | |||
madai26¶Ò»»¹ó±ö
|
[½»Á÷]
¡¾ÇóÖú¡¿ÓÐûÓгæ×Ó°ïÎÒ²éÒ»ÏÂfasidotrilÕâ¸öÒ©ÔÚ¹úÍâÓÐûÓÐÉÏÊУ¿ ÒÑÓÐ2È˲ÎÓë
|
|
ÒòΪÎÒÃǵ¥Î»Ã»É¶Êý¾Ý¿â£¬ËùÒԲ鲻µ½¡£ fasidotril ·¨Î÷¶àÇú ACE/NEPË«ÏòÒÖÖÆ¼Á ÁÙ´²ÊÔÑé×öµ½3ÆÚ£¬µ«ºóÀ´¾ÍûÏÂÎÄÁË£¬ÄÄλºÃÐĵijæ×Ó°ï¸öÃ¦ÄØ£¿°ïÎÒ°ÑËüÓÐûÓÐÉÏÊУ¬ÔÚÄÄÉÏÊеIJéһϣ¿ |
» ²ÂÄãϲ»¶
¸÷¹úºÍ¹ú¼Ê×éÖ¯ÏÖÐÐÒ©µä×¢ÉäÓÃË®ÖÊÁ¿±ê×¼
ÒѾÓÐ0È˻ظ´
ÇóÖúÓÃ΢Æ×Êý¾Ý¿â²éѯ
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ281È˻ظ´
¼ÆË㻯ѧÓëÈ˹¤ÖÇÄÜÇý¶¯µÄMOFsÐÔÄÜÔ¤²âÓëɸѡ¼¼Êõ
ÒѾÓÐ0È˻ظ´
ÑÐÈýʵÑéÇóÖ¸µ¼
ÒѾÓÐ0È˻ظ´
½ðÊô²ÄÁ϶à³ß¶È¼ÆËãÄ£Äâ¼¼ÊõÓëÓ¦ÓãºÎ¢¹Û»úÀíµ½ºê¹ÛÐÔÄܵɹ¤×÷
ÒѾÓÐ0È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧ07ÉúÎïѧºÍ08ÉúÎïÓëÒ½Ò©´óÁ¿µ÷¼Á
ÒѾÓÐ26È˻ظ´
ҩѧר˶É격
ÒѾÓÐ5È˻ظ´
¡¾ÕÐÆ¸¡¿Çå±±£¨¼ÃÄÏ£©ÉúÎï¿Æ¼¼ÕÐÆ¸AIÖÆÒ©Ñз¢¼ÆËãÈ˲Å
ÒѾÓÐ15È˻ظ´
¿ÉÄÜÉϲ»Á˰¶£¿ÓÐÌõ¼þµÄ¿ÉÒÔ¿¼ÂÇÆäËû³ö·
ÒѾÓÐ0È˻ظ´
100701ҩѧרҵÕе÷¼Á£¬5¸öÃû¶î£¬Ò©Îﻯѧרҵ£¬Ö÷ÒªÊÇÌìȻҩÎﻯѧ·½Ïò¼ÓÒ©Àí
ÒѾÓÐ2È˻ظ´
nkbeholder
¹ÜÀíÔ±
![]()
![]()
![]()
![]()
- DRDEPI: 1
- Ó¦Öú: 11 (СѧÉú)
- ½ð±Ò: 2945.1
- É¢½ð: 4
- ºì»¨: 5
- Ìû×Ó: 748
- ÔÚÏß: 303.7Сʱ
- ³æºÅ: 202353
- ×¢²á: 2006-03-01
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
¡ï ¡ï
madai26(½ð±Ò+2):лл²ÎÓë
warlen(½ð±Ò+1):лл²ÎÓë 2010-08-04 15:15:09
madai26(½ð±Ò+2):лл²ÎÓë
warlen(½ð±Ò+1):лл²ÎÓë 2010-08-04 15:15:09
|
ÕâÉÏÃæÐ´µ½2ÆÚ¾ÍÖÐÖ¹ÁË¡£ Originator Company: Bioprojet (France) Parent Company: Bioprojet Licensee: Eli Lilly Highest Phase: Discontinued II Development Status: Discontinued II, France, Congestive heart failure Discontinued II, France, Hypertension Discontinued Preclinical, France, Postmyocardial infarction Introduction: Fasidotril, the prodrug of its active metabolite fasidoprilat, is a mixed inhibitor of ACE and neutral endopeptidase. It was undergoing phase II development with Bioprojet in France for the treatment of congestive heart failure and hypertension. It was also in preclinical development for postmyocardial infarction. However, development appears to have been discontinued. In October 2001, Bioprojet and Eli Lilly announced a development and commercialisation collaboration. Under the terms of the agreement, Lilly received exclusive worldwide commercialisation rights excluding Japan and certain countries in Europe. Lilly was to continue to develop fasidotril through to registration, and was to manufacture the finished product; Bioprojet was to manufacture the bulk material. |
2Â¥2010-08-04 14:45:13
mrzouhao
°æÖ÷
![]()
![]()
![]()
![]()
- DRDEPI: 1
- Ó¦Öú: 179 (¸ßÖÐÉú)
- ¹ó±ö: 0.108
- ½ð±Ò: 100882
- É¢½ð: 11601
- ºì»¨: 134
- ɳ·¢: 22
- Ìû×Ó: 46786
- ÔÚÏß: 4409.4Сʱ
- ³æºÅ: 201350
- ×¢²á: 2006-02-28
- רҵ: Ò©¼Áѧ
3Â¥2010-08-04 15:13:10














»Ø¸´´ËÂ¥